Croyal, Mikaël
Wargny, Matthieu
Chemello, Kevin
Chevalier, Chloé
Blanchard, Valentin
Bigot-Corbel, Edith
Lambert, Gilles
Le May, Cédric
Hadjadj, Samy
Cariou, Bertrand
Clinical trials referenced in this document:
Documents that mention this clinical trial
Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes
https://doi.org/10.1186/s12933-022-01452-5
Documents that mention this clinical trial
Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes
https://doi.org/10.1186/s12933-022-01452-5
Article History
Received: 16 November 2021
Accepted: 20 January 2022
First Online: 7 February 2022
Declarations
:
: The IT-DIAB (Innovation Thérapeutique-Diabète) study is registered as NCT01218061 and NCT01432509. The institutional ethics committee approved the protocol, and all of the reported investigations have been carried out in accordance with the principles of the Declaration of Helsinki as revised in 2008. All participants provided their written informed consent for research use of the anonymized data collected according to local regulation.
: All authors consent to this publication.
: There are no competing interests related to this work to disclose.